RxDoctor Payments Data

Ajish Pillai, MD

Internal Medicine · East Patchogue, NYNPI 1306157763

Payments from drug & device makers

$3,715in general payments, 2019–2025

Across 233 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$376
  • Pfizer$235
  • Intercept Pharmaceuticals, Inc.$222
  • Ferring Pharmaceuticals Inc.$213
  • Sanofi$211
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,715100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,715 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$145,391
Medicare patients
461
Services billed
924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide79$108,785
Humira(Cf) PenAdalimumab13$84,226
Mesalamine38$58,718
IbsrelaTenapanor Hcl21$39,282
ClenpiqSod Picosulf/Mag Ox/Citric Ac127$21,606
CreonLipase/Protease/Amylase13$20,734
PentasaMesalamine13$15,653
MotegrityPrucalopride Succinate13$10,993
Dexlansoprazole DrDexlansoprazole22$9,994
MovantikNaloxegol Oxalate17$9,370
Lubiprostone53$9,098
Ursodiol22$6,166
Pantoprazole Sodium488$5,054
Esomeprazole Magnesium75$4,669
CholestyramineCholestyramine (With Sugar)16$2,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,302$129,51892 claims
Ardelyx, Inc.Ibsrela$201$39,28221 claims
Ferring Pharmaceuticals Inc.Clenpiq$213$21,606127 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$48$10,99313 claims
Redhill Biopharma Inc.Movantik$26$9,37017 claims
Braintree Laboratories, Inc.Sutab$32$1,92912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in East Patchogue

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →